| Identification | Back Directory | [Name]
Emibetuzumab | [CAS]
1365287-97-3 | [Synonyms]
Emibetuzumab
Emibetuzumab (anti-MET)
Research Grade Emibetuzumab(DHC34201) |
| Hazard Information | Back Directory | [Description]
Emibetuzumab is a bivalent antibody that blocks HGF- and MET-receptor interaction,
leading to MET internalization and degradation. | [Uses]
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer[1]. | [Clinical Use]
A phase I study determined a tolerable dose for emibetuzumab to be 700–2000 mg as a monotherapy and
in combination with erlotinib in NSCLC patients. It is currently being investigated in phase II in combination with erlotinib. | [in vivo]
Emibetuzumab (LY2875358) (10 mg/kg; i.v.; once a week for 5 weeks) inhibits in vivo growth of glioblastoma U87MG xenograft tumors in mice[1].
Emibetuzumab (10 or 20 mg/kg; i.v.; single) downregulates levels of MET and pMET in the tumors of mice[1].
Emibetuzumab (10 mg/kg; i.v.; once a week for 3, 5 or 6 weeks) exhibits antitumor effects on MET-amplified xenograft mouse tumor models[1]. | Animal Model: | Athymic nude mice (U87MG tumor xenograft model)[1]. | | Dosage: | 10 mg/kg | | Administration: | Intravenous injection, once a week for 5 weeks. | | Result: | Demonstrated a significant inhibition of tumor growth. |
| Animal Model: | Athymic nude mice (MKN45 xenograft tumor model)[1]. | | Dosage: | 10 or 20 mg/kg | | Administration: | Intravenous injection, single. | | Result: | Reduced MET and pMET in the tumors by approximately 50% at both the 10 and 20 mg/kg doses by 72 hours post dose, and the reductions persisted to 14 days. |
| Animal Model: | Athymic nude mice (MET-amplified xenograft mouse tumor models)[1]. | | Dosage: | 10 mg/kg | | Administration: | Intravenous injection, once a week for 3, 5 or 6 weeks. | | Result: | Resulted in a marked reduction in tumor growth in the MKN45/SNU-5/EBC-1 gastric xenograft tumors. |
| [References]
[1] Liu L, et al. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res. 2014 Dec 1;20(23):6059-70. DOI:10.1158/1078-0432.CCR-14-0543 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|